A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

This study is testing a new drug called BT5528 in patients with metastatic pancreatic ductal adenocarcinoma — the most common and aggressive type of pancreatic cancer that has spread to other parts of the body. BT5528 is an antibody-drug conjugate that targets a protein called EphA2, which is found on many pancreatic cancer cells, and delivers a chemotherapy payload directly to the cancer. **You may be eligible if:** - You are 18 years of age or older - You have been diagnosed with metastatic pancreatic ductal adenocarcinoma, confirmed by biopsy - You have received exactly one prior line of treatment and your cancer has progressed - You have at least one measurable tumor on imaging - You are in good general health (ECOG performance status 0 or 1) - You have sufficient tumor tissue available for biomarker testing - Your kidney, liver, and blood counts are adequate **You may NOT be eligible if:** - You have received prior treatment with taxane drugs (e.g., paclitaxel) for your pancreatic cancer - You have received any drug containing the chemotherapy agent MMAE previously - Your cancer has microsatellite instability-high (MSI-H) status and you are eligible for immunotherapy - You have received chemotherapy or radiotherapy within 14 days before starting the study drug - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.